Onapristone

Add links
Source: Wikipedia, the free encyclopedia.
Onapristone
Clinical data
Other namesZK-89299; ZK-299; AR-18; IVV-1001; 11β-(4-(Dimethylamino)phenyl)-17α-hydroxy-17β-(3-hydroxypropyl)-13α-estra-4,9-dien-3-one
Drug classAntiprogestogen
Identifiers
  • (8S,11R,13R,14S,17S)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
JSmol)
  • C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C
  • InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
  • Key:IEXUMDBQLIVNHZ-YOUGDJEHSA-N

Onapristone (

contraceptive, but was discontinued during phase III clinical trials in 1995 due to findings that liver function abnormalities developed in a majority patients.[5][6][7]

Onapristone has been found to be effective in the treatment of breast cancer.[8][5][9]

As of 2016, onapristone has re-emerged and is under development for the treatment of prostate cancer, currently in phase II clinical trials.[10] It was also under development for the treatment of endometrial cancer, breast cancer, ovarian cancer, and uterine cancer, but was discontinued for these indications in favor of focusing on prostate cancer.[10]

See also

References

  1. PMID 18637487. Onapristone, p. 102, at Google Books
  2. ISBN 978-1-4757-2087-7. Onapristone, p. 903, at Google Books
  3. ISBN 978-94-010-5907-7. Onapristone, p. 207, at Google Books
  4. ^
    ISBN 978-1-4612-8650-9. Onapristone, p. 134, at Google Books
  5. ^
    PMID 10448262
    .
  6. PMID 7573244
    .
  7. ISBN 978-3-540-69742-8. Onapristone, p. 338, at Google Books
  8. S2CID 25524094
    .
  9. PMID 30304013
    .
  10. ^ a b "Onapristone - Context Therapeutics". Adis Insight. Springer Nature Switzerland AG.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Onapristone&oldid=1188997982"